Huperzine A
Research reviewed: Up until 03/2026
Huperzine A (Huperzia serrata) is a dietary supplement with 9 published peer-reviewed studies involving 337 participants, researched for Alzheimer's Disease & Cognitive Decline, Healthy Adults & Memory Enhancement, Neuroprotection & Antioxidant and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Alzheimer's Disease & Cognitive Decline
StrongHealthy Adults & Memory Enhancement
ModerateNeuroprotection & Antioxidant
ModerateMood & Depression
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Alzheimer's Disease & Cognitive Decline
To evaluate Huperzine A on cognitive function in Alzheimer's disease patients
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate Huperzine A on cognitive function in Alzheimer's disease patients
Dose
400 mcg/day Huperzine A
Participants
103 Alzheimer's patients
Duration
12 weeks
Results
Significant improvements in ADAS-cog scores (p<0.01), MMSE, and clinical global impression. 58% of Huperzine group showed significant cognitive improvement vs 36% placebo.
How They Measured It
ADAS-cog, MMSE, Clinical Global Impression
To assess Huperzine A in vascular dementia and multi-infarct dementia
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess Huperzine A in vascular dementia and multi-infarct dementia
Dose
200 mcg twice daily
Participants
78 patients with vascular dementia
Duration
12 weeks
Results
Significant improvements in MMSE, ADL scores, and behavioural assessments vs placebo. CGI improvement in 71.8% of Huperzine group. Well tolerated.
How They Measured It
MMSE, ADL, behavioural assessment, CGI
To assess the efficacy and safety of Huperzine A in Alzheimer's disease
Study Type
Systematic review and meta-analysis
Purpose
To assess the efficacy and safety of Huperzine A in Alzheimer's disease
Dose
200-400 mcg/day
Participants
Meta-analysis of 6 RCTs (454 patients)
Duration
8-24 weeks
Results
Significant improvements in MMSE (MD +2.99), ADAS-cog, and ADL vs placebo. Effect comparable to conventional cholinesterase inhibitors. Safe and well-tolerated.
How They Measured It
MMSE, ADAS-cog, ADL across 6 RCTs
Healthy Adults & Memory Enhancement
To evaluate Huperzine A on memory in adolescent students
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate Huperzine A on memory in adolescent students
Dose
100 mcg twice daily
Participants
34 junior high school students with learning difficulties
Duration
4 weeks
Results
Significant improvements in memory quotient and ability to learn new information (p<0.001). Memory retention scores improved 36% more than placebo.
How They Measured It
Wechsler Memory Scale, learning and retention tests
To examine acute effects of Huperzine A on cognition in young healthy adults
Study Type
Randomised, placebo-controlled, crossover
Purpose
To examine acute effects of Huperzine A on cognition in young healthy adults
Dose
50 mcg single dose
Participants
20 healthy young adults
Duration
Acute crossover
Results
Significant improvements in sustained attention and working memory accuracy (p<0.05). Serum AChE activity reduced by 23%. Performance benefits consistent with AChE inhibition.
How They Measured It
Attention, working memory, sustained attention, serum AChE
Neuroprotection & Antioxidant
To evaluate Huperzine A on neuroprotective markers in Alzheimer's patients
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate Huperzine A on neuroprotective markers in Alzheimer's patients
Dose
400 mcg/day
Participants
60 early Alzheimer's disease patients
Duration
24 weeks
Results
Significant improvement in MMSE and ADL. Reduction in 8-OHdG oxidative marker. Beta-amyloid accumulation markers trending lower. Neuroprotective effects suggested.
How They Measured It
CSF beta-amyloid, tau, 8-OHdG, brain imaging
To investigate neuroprotective mechanisms of Huperzine A beyond AChE inhibition
Study Type
In vitro and animal study (mechanistic)
Purpose
To investigate neuroprotective mechanisms of Huperzine A beyond AChE inhibition
Dose
Various concentrations
Participants
Cell and animal models
Duration
Various
Results
Huperzine A demonstrated NMDA receptor antagonism, antioxidant activity, anti-apoptotic effects, and reduced amyloid precursor protein processing. Multi-modal neuroprotection confirmed.
How They Measured It
NMDA receptor activity, oxidative stress, apoptosis, amyloid precursor protein
Mood & Depression
To evaluate Huperzine A as adjunctive treatment for depression
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate Huperzine A as adjunctive treatment for depression
Dose
200 mcg/day Huperzine A
Participants
36 patients with major depressive disorder
Duration
8 weeks
Results
Significant additional reduction in HAM-D scores vs antidepressant alone (p=0.03). Cognitive symptoms improved more in combination group. Well tolerated.
How They Measured It
HAM-D, MADRS, CGI, salivary cortisol
To review clinical evidence for Huperzine A in neurological and psychiatric conditions
Study Type
Systematic review
Purpose
To review clinical evidence for Huperzine A in neurological and psychiatric conditions
Dose
Various
Participants
Systematic review
Duration
Various
Results
Consistent evidence for cognitive benefits in dementia. Preliminary evidence for depression and healthy cognition. AChE inhibition well-established. Good safety profile in clinical doses.
How They Measured It
Systematic review of RCTs
Frequently Asked Questions
Common questions about Huperzine A research
There are currently 9 peer-reviewed studies on Huperzine A (Huperzia serrata), involving 337 total participants. Research covers Cognitive function, Memory, Alzheimer's disease and 2 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Huperzine A has been researched for: Cognitive function, Memory, Alzheimer's disease, Neuroprotection, Mood. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
